The Ritedose Corporation

What The Ritedose Corporation does

The Ritedose Corporation is a privately held pharmaceutical CDMO and generics manufacturer founded in 1995 in Columbia, South Carolina, and acquired by Novo Holdings A/S (the holding company of the Novo Nordisk Foundation) in January 2022. The company specializes in Blow-Fill-Seal (BFS) aseptic manufacturing — an automated process that extrudes polymer into a mold, fills the formed container with product, and seals it in a continuous sterile operation — and is the largest US CDMO dedicated to sterile BFS technology, with current annual capacity of 1.8 billion doses and over 12 billion doses delivered since 2012 without patient interruption. Ritedose operates two business lines: (1) a CDMO division providing individualized contract development and manufacturing services for pharmaceutical clients from clinical trials through full-scale commercialization of ophthalmic, respiratory, and injectable medications; and (2) a generics division (Ritedose Pharmaceuticals) marketing its own portfolio of inhalation solutions, ophthalmic products, and oral liquids through wholesalers, major retail pharmacy chains, and hospitals. Ritedose commands over 45% of the US nebulized medication market and reports 100% customer retention over 25 years, with anchor clients including Viatris, Verona Pharma, Tenpoint Therapeutics, and a broad roster of global generics manufacturers.

The company runs on a B2B contract manufacturing and wholesale distribution model, with pricing not publicly disclosed and governed by multi-year contracts subject to price-list revision. It is currently executing an aggressive expansion: a 105-acre Ritedose Performance Park acquired in February 2024 with a $81M+ multi-year buildout, a seventh Syntegon packaging line doubling vial-processing capacity to 160-170 million units annually, a $17M cGMP laboratory expansion, and a 225,000 sq ft distribution and logistics center unveiled in June 2025. The workforce has scaled from 200+ to 600+ employees across recent years. The company has been awarded the SCbio 2026 Life Sciences Pinnacle Award and was recognized as the #1 American Heart Association Field Day company nationally in 2023. Ritedose operates exclusively within the United States and has no disclosed international footprint.

Name

The Ritedose Corporation

Legal name

The Ritedose Corporation

Website

https://ritedose.com

Company type

Private

Founded year

1995

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Ritedose Corporation is a US-based CDMO and generics manufacturer specializing in sterile Blow-Fill-Seal (BFS) technology, producing inhalation, ophthalmic, oral, and injectable unit-dose pharmaceuticals for large pharma, wholesalers, retail pharmacies, and hospitals.

Ownership category

akta.pro rank

Product category

Sterile Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

Keywords

• Sterile pharmaceutical manufacturing
• Blow-fill-seal technology
• Contract drug manufacturing
• Generic inhalation solutions
• Unit-dose medications

Headquarters

HQ city

Columbia

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. CDMO Services: Contract development and manufacturing services for pharmaceutical companies from clinical trials through full-scale commercialization of ophthalmic, respiratory, and injectable medications using BFS technology.
2. Generic Pharmaceuticals: Development and marketing of company's own portfolio of generic drugs including inhalation solutions, ophthalmic products, and oral liquids sold to wholesalers, retail pharmacies, and hospitals.
3. 503B Outsourcing: Sterile compounding services for medically necessary drugs that are in short supply, supplying hospital pharmacies across the country.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Core offering

The Ritedose Corporation is the largest U.S. Contract Development and Manufacturing Organization (CDMO) specializing in sterile Blow-Fill-Seal (BFS) technology, providing contract manufacturing services for pharmaceutical companies from clinical trials through full-scale commercialization. In parallel, the company operates a generics division (Ritedose Pharmaceuticals) that develops, manufactures, and markets its own portfolio of generic inhalation solutions, ophthalmic products, and oral liquids sold to wholesalers, retail pharmacy chains, and hospitals. Ritedose also developed the proprietary SuredoseRx single-dose liquid medication dispenser.

Product overview

The Ritedose Corporation is a CDMO and generics manufacturer specializing in sterile Blow-Fill-Seal (BFS) technology. The company operates two core divisions: (1) CDMO Services for contract development and manufacturing of sterile pharmaceuticals, and (2) a Generics division offering its own portfolio of generic medications. The BFS technology platform enables production of sterile unit-dose inhalation products, ophthalmic medications, oral liquids, and injectables. Key products include respiratory generics (Tobramycin, Albuterol, Formoterol, Arformoterol, Cromolyn Sodium), manufactured drug products (Yuvezzi for Tenpoint Therapeutics, Ohtuvayre for Verona Pharma), and the proprietary SuredoseRx™ liquid medication dispenser. Ritedose also previously operated a 503B outsourcing division for hospital compounding, though resources have since been pivoted to FDA-approved drug products. Products are available for wholesalers, retail pharmacy chains, and hospitals across the U.S.

Differentiator

Problem solved

Functional benefit

Products and services

• CDMO Services (Contract Development and Manufacturing)
• Generic Pharmaceuticals
• SuredoseRx Liquid Medication Dispenser
• Tobramycin Inhalation Solution
• Albuterol Sulfate Inhalation Solution
• Formoterol Fumarate Inhalation Solution
• Arformoterol Tartrate Inhalation Solution
• Cromolyn Sodium Inhalation Solution
• Cromolyn Sodium Oral Solution
• Atropine Sulfate Injection
• Ohtuvayre (ensifentrine)
• Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution)
• 503B Outsourcing Services

Quantifiable outcome

• 12+ billion doses delivered since 2012 with no patient interruptions
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core, supporting and major.

• Tenpoint TherapeuticscoreStrategic or Co-development Partner · 8 April 2026Ritedose selected as manufacturing partner for YUVEZZI (carbachol and brimonidine tartrate), the first and only FDA-approved dual-agent eye drop for treating presbyopia. Partnership positioned for commercial readiness and supply security for national launch.
• Syntegon TechnologycoreTechnology or Integration · 16 April 2025Ritedose relies on Syntegon Technology for processing and packaging solutions. Added seventh Syntegon packaging line in 2025 to double capacity for individually wrapped vial medications, processing 160-170 million vials annually.
• Newberry CollegesupportingStrategic or Co-development Partner · 21 January 2025Launched Pharmaceutical Manufacturing program starting summer 2025 - a 30-hour bachelor's program for students with associate degrees. 10 async courses focused on quality, compliance, and process optimization. First institution in SC to offer this specialized program.
• inSpringsupportingStrategic or Co-development Partner · 8 October 2024Workforce development partnership to develop talent pipeline for first-gen and international candidates. Manages international worker visa process and provides workforce readiness training aligned with hiring needs.
• Benedict CollegesupportingStrategic or Co-development Partner · 8 October 2024HBCU partnership through RISE (Ritedose International Student Engagement) program - workforce initiative for international STEM students. Creates pipeline for laboratory positions at Ritedose.
• Verona PharmacoreStrategic or Co-development Partner · 17 September 2024Ritedose serves as development and manufacturing partner for Ohtuvayre (ensifentrine), Verona Pharma's first-in-class COPD drug approved by FDA in June 2024. Ritedose manufactures national launch quantities for this groundbreaking respiratory therapy - the first inhaled product with a novel mechanism of action for COPD in over 20 years.
• Dispensary of HopemajorStrategic or Co-development Partner · 12 August 2024Ritedose pledges long-term supply of critical respiratory medications for low-income and uninsured patients. Committed 1 million doses in 2024, building on 124,000 doses in 2023. Joined Hope Alliance campaign with other pharmaceutical companies including Viatris, Amneal, Aurobindo, and Hikma.
• ApiJectmajorStrategic or Co-development Partner · 19 November 2020Selected as subcontractor for production of single-dose prefilled syringes intended for administering COVID-19 vaccines. Repurposed and upgraded equipment to fill and finish up to 45 million prefilled syringes per month.

Scale indicators10 records

Recent moves12 records

Expansion highlights5 records

Direct peers

• Recipharm: Large European-based CDMO offering sterile fill-finish, inhalation, and injectables manufacturing across multiple dosage forms. Competes with Ritedose for ophthalmic, respiratory, and injectable CDMO contracts from pharma sponsors globally.
• Nephron Pharmaceuticals: South Carolina-based pharmaceutical manufacturer operating its own generics, contract manufacturing, and 503B outsourcing businesses. Directly competes with Ritedose in sterile inhalation solutions, ophthalmics, and BFS-adjacent formats, particularly for U.S. hospital and retail pharmacy customers.
• Gerresheimer AG: Global manufacturer of primary packaging and drug delivery systems including BFS-based sterile containers. Comparable to Ritedose in BFS technology depth and serves many of the same pharma CDMO customers for ophthalmic and respiratory unit-dose products.
• ApiJect: Single-dose prefilled syringe manufacturer built around aseptic BFS-style technology. Ritedose has been a subcontractor for ApiJect's COVID-19 syringe program, and the two compete for aseptic, single-dose, high-volume government and commercial contracts.
• Hovione: Contract development and manufacturing organization specializing in inhalation and sterile injectable drug products. Direct competitor to Ritedose in particle engineering and inhalation CDMO services for respiratory and ophthalmic indications.

Broad incumbents

• AptarGroup: Provider of drug delivery solutions, dispensing systems, and active material science serving pharmaceutical, beauty, and home markets. Aptar's Pharma segment offers inhalation, ophthalmic, and nasal delivery systems that overlap with Ritedose's device-plus-fill business (e.g., SuredoseRx).
• Catalent: One of the largest global CDMOs with a broad portfolio spanning softgels, biologics, sterile injectables, and inhalation. Overlaps with Ritedose in sterile fill-finish and inhalation CDMO services, but offers a much broader technology stack at significantly greater scale.
• Patheon (Thermo Fisher Scientific CDMO): Pharma services division of Thermo Fisher offering end-to-end drug development and commercial manufacturing. Competes with Ritedose for large pharma CDMO relationships across sterile and inhalation modalities.
• West Pharmaceutical Services: Global leader in primary packaging, elastomers, and drug delivery systems used by sterile injectable and inhalation drug manufacturers. Closely allied to — and competing for share of — Ritedose's CDMO and device-delivery customers.

Emerging players

• Curia (formerly AMRI): Integrated CDMO offering API development, sterile fill-finish, and drug product manufacturing across multiple modalities. An emerging competitor in sterile injectables and inhaled drug product CDMO spaces where Ritedose competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/the-ritedose-corporation-trc-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Ritedose Corporation